Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 40:669-675
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chan, A. W.
Right arrow Articles by Ellis, S. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chan, A. W.
Right arrow Articles by Ellis, S. G.

CLINICAL STUDY: ADJUNCTIVE THERAPY AND PCI

Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention

Albert W. Chan, MD, MS, FRCP(C)*, Martin J. Quinn, MD, PhD*, Deepak L. Bhatt, MD*, Derek P. Chew, MBBS, FRCP(A)*, David J. Moliterno, MD, FACC*, Eric J. Topol, MD, FACC* and Stephen G. Ellis, MD, FACC*,*

* Section of Interventional Cardiology, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA

Manuscript received December 30, 2001; revised manuscript received April 12, 2002, accepted May 15, 2002.

* Reprint requests and correspondence: Dr. Stephen G. Ellis, Sones Cardiac Catheterization Laboratories, The Cleveland Clinic Foundation, 9500 Euclid Avenue, F25, Cleveland, Ohio 44195, USA.
elliss{at}ccf.org

OBJECTIVES: The goal of this study was to evaluate the mortality benefit of beta-blockers after successful percutaneous coronary intervention (PCI).

BACKGROUND: Beta-blockers reduce mortality after myocardial infarction (MI), though limited data are available regarding their role after successful PCI.

METHODS: Each year from 1993 through 1999, the first 1,000 consecutive patients undergoing PCI were systematically followed up. Patients presenting with acute or recent MI, shock, or unsuccessful revascularization procedures were excluded from the analysis. Clinical, procedural, and follow-up data of beta-blocker-treated and non-beta-blocker-treated patients were compared. A multivariate survival analysis model using propensity analysis was used to adjust for heterogeneity between the two groups.

RESULTS: Of the 4,553 patients, 2,056 (45%) were treated with beta-blockers at the time of the procedure. Beta-blocker therapy was associated with a mortality reduction from 1.3% to 0.8% at 30 days (p = 0.13) and a reduction from 6.0% to 3.9% at one year (p = 0.0014). This survival benefit of beta-blockers was independent of left ventricular function, diabetic status, history of hypertension, or history of MI. Using propensity analysis, beta-blocker therapy remained an independent predictor for one-year survival after PCI (hazard ratio, 0.63; 95% confidence interval, 0.46 to 0.87; p = 0.0054).

CONCLUSIONS: Within this large prospective registry, beta-blocker use was associated with a marked long-term survival benefit among patients undergoing successful elective percutaneous coronary revascularization.

Abbreviations and Acronyms
  ACE
  angiotensin-coverting enzyme
  CABG
  coronary artery bypass grafting
  CAD
  coronary artery disease
  CI
  confidence interval
  CK
  creatine kinase
  COPD
  chronic obstructive pulmonary disease
  LVEF
  left ventricular ejection fraction
  MI
  myocardial infarction
  PCI
  percutaneous coronary intervention




This article has been cited by other articles:


Home page
Circ Cardiovasc IntervHome page
L. Venkitachalam, K. E. Kip, F. Selzer, R. L. Wilensky, J. Slater, S. R. Mulukutla, O. C. Marroquin, P. C. Block, D. O. Williams, S. F. Kelsey, et al.
Twenty-Year Evolution of Percutaneous Coronary Intervention and Its Impact on Clinical Outcomes: A Report From the National Heart, Lung, and Blood Institute-Sponsored, Multicenter 1985-1986 PTCA and 1997-2006 Dynamic Registries
Circ Cardiovasc Interv, February 1, 2009; 2(1): 6 - 13.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
B. Ibanez, S. Prat-Gonzalez, W. S. Speidl, G. Vilahur, A. Pinero, G. Cimmino, M. J. Garcia, V. Fuster, J. Sanz, and J. J. Badimon
Early Metoprolol Administration Before Coronary Reperfusion Results in Increased Myocardial Salvage: Analysis of Ischemic Myocardium at Risk Using Cardiac Magnetic Resonance
Circulation, June 12, 2007; 115(23): 2909 - 2916.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
I. Atar, M. E. Korkmaz, I. A. Atar, O. Gulmez, B. Ozin, H. Bozbas, T. Erol, A. Aydinalp, A. Yildirir, M. Yucel, et al.
Effects of metoprolol therapy on cardiac troponin-I levels after elective percutaneous coronary interventions
Eur. Heart J., March 1, 2006; 27(5): 547 - 552.
[Abstract] [Full Text] [PDF]


Home page
Eur Heart JHome page
J. Herrmann
Peri-procedural myocardial injury: 2005 update
Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
W. A. Jaber, R. J. Lennon, V. Mathew, D. R. Holmes Jr, A. Lerman, and C. S. Rihal
Application of Evidence-Based Medical Therapy Is Associated With Improved Outcomes After Percutaneous Coronary Intervention and Is a Valid Quality Indicator
J. Am. Coll. Cardiol., October 18, 2005; 46(8): 1473 - 1478.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
D. P. Faxon
Beta-blocker therapy and primary angioplasty: What is the controversy?
J. Am. Coll. Cardiol., May 19, 2004; 43(10): 1788 - 1790.
[Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement